Pellegrino M.
- Country
- Italy
- Department
- 138026: Ematologia
Research Overview
- Blinatumomab and Combination Therapy Versus Standard of Care in Older Adults With Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- A Phase II Study of Teclistamab Combined with Autologous Lymphocyte Infusion in Relapsed/Refractory Multiple Myeloma
- Phase 3 Randomized Trial of Teclistamab Plus Daratumumab SC vs. Daratumumab SC with Pomalidomide and Dexamethasone or Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 295 of 486 partner sites.
Specializations
Leukemia Research
Specializes in various forms of leukemia, with particular emphasis on Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Chronic Myeloid Leukemia. Investigates novel therapeutic approaches including BCL-2 inhibitors and targeted therapies for specific genetic mutations.
- IDH1-mutated AML treatments
- BCR-ABL1+ targeted therapies
- NPM1-mutated AML interventions
Multiple Myeloma Studies
Focuses on innovative treatments for Multiple Myeloma, including both newly diagnosed and relapsed/refractory cases. Explores combination therapies involving proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
- High-risk smoldering multiple myeloma
- Post-transplant maintenance therapy
- Novel drug combinations
Specialized Hematologic Conditions
Conducts research in rare and complex hematologic disorders including Myelofibrosis, Myelodysplastic Syndromes, and Peripheral T-cell Lymphomas. Investigates targeted therapies and novel treatment combinations.
- Hairy Cell Leukemia treatments
- Warm autoimmune hemolytic anemia
- Diffuse large B-cell lymphoma
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.